Last Updated: September 24, 2026

Patent: 7,939,632

✉ Email this page to a colleague

Summary for Patent: 7,939,632

Title:	Proteolytically cleavable fusion proteins with high molar specific activity
Abstract:	The invention relates to therapeutic fusion proteins in which a coagulation factor is fused to a half-life enhancing polypeptide, and in which both are connected by a linker peptide that is proteolytically cleavable. The cleavage of such linkers liberates the coagulation factor from activity-compromising steric hindrance caused by the half-life enhancing polypeptide and thereby allows the generation of fusion proteins may show relatively high molar specific activity when tested in coagulation-related assays. Furthermore, the fact that the linker is cleavable can enhance the rates of inactivation and/or elimination after proteolytic cleavage of the peptide linker compared to the rates measured for corresponding therapeutic fusion proteins linked by the non-cleavable linker having the amino acid sequence GGGGGGV.
Inventor(s):	Hubert Metzner, Thomas Weimer, Stefan Schulte
Assignee:	CSL Behring GmbH Deutschland
Application Number:	US12/000,739
Patent Claims:	see list of patent claims

Details for Patent 7,939,632

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Csl Behring Lengnau Ag	IDELVION	coagulation factor ix (recombinant), albumin fusion protein	For Injection	125582	4-Mar-16	7,939,632	2027-12-17
Csl Behring Lengnau Ag	IDELVION	coagulation factor ix (recombinant), albumin fusion protein	For Injection	125582	30-May-18	7,939,632	2027-12-17
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

International Patent Family for US Patent 7,939,632

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration
Australia	2007260185	⤷ Start Trial
Australia	2013202566	⤷ Start Trial
Canada	2655248	⤷ Start Trial
Denmark	2032607	⤷ Start Trial
Denmark	2256135	⤷ Start Trial
Denmark	3564267	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.